M26-033 - Biomarker Study of Targeted Therapies in Rheumatoid Arthritis (Synovial Biopsy)

• Research type

  Research Study

• Full title

  A Phase 1b Multicenter, Platform, Open-label, Interventional Biomarker Study of Targeted Therapies for the Treatment of Adult Subjects with Rheumatoid Arthritis

• IRAS ID

  1013069

• Contact name

  Bernhard Dodell

• Contact email

  global-clinical-trials@abbvie.com

• Sponsor organisation

  AbbVie Deutschland GmbH & Co. KG

• Research summary

  An open-label study evaluating the safety, tolerability and biomarkers of multiple targeted therapies in adult participants with rheumatoid arthritis (RA).

• REC name

  London - Hampstead Research Ethics Committee

• REC reference

  26/LO/0280

• Date of REC Opinion

  22 May 2026

• REC opinion

  Further Information Favourable Opinion